Skip to main content
ATRA logo

Atara Biotherapeutics, Inc.

ATRANASDAQHealthcareBiotechnology

$8.30Today:- (-)1Y −33.22%

As of Oct 27, 2026 close

Market cap
$124.77M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.92$19.15
Volume (live)
-
Avg. volume (3M)
35.52K

Atara Biotherapeutics (ATRA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Atara Biotherapeutics used $50.94M of cash in operating activities. Free cash flow was −$50.94M.

Atara Biotherapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Atara Biotherapeutics, Inc. (ATRA) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income32.69-85.40-276.13-228.30-340.14-306.62-290.98-230.70-119.49
Depreciation & Amortization2.125.054.835.659.358.337.073.730.96
Deferred Income Tax0.000.000.000.001.790.960.00-1.890.00
Stock Based Compensation9.7527.0045.3953.8453.8751.3551.7033.8223.10
Change in Working Capital-104.74-30.9615.34-61.4752.5863.69-4.1515.007.20
Change in Accounts Receivable0.2332.636.11-39.240.26-1.250.000.000.00
Change in Inventory10.66-4.43-8.12-1.593.34-1.250.000.000.00
Change in Accounts Payable-4.240.69-3.13-9.219.07-0.824.21-1.962.16
Change in Other Working Capital0.7315.8316.80-6.092.064.50-8.3616.965.04
Other Operating Activities9.2415.8316.80-40.152.061.670.730.260.73
Net Cash from Operating Activities-50.94-68.72-192.98-270.43-220.52-180.76-235.63-179.77-87.50
Investing Activities
Capital Expenditures0.00-0.25-1.22-4.19-10.58-4.51-5.73-35.93-20.23
Acquisitions0.950.000.000.00-32.84116.220.000.000.00
Purchases of Investments-7.89-19.67-83.65-180.59-301.13-116.22-270.23-466.49-176.46
Sales/Maturities of Investments25.0928.54208.71292.97333.97309.65336.26306.13296.60
Other Investing Activities0.000.000.0394.7732.84-116.220.16-160.36-1.20
Net Cash from Investing Activities18.158.62123.87202.9622.26-120.7360.46-196.2998.71
Financing Activities
Debt Repayment-0.25-0.89-0.95-0.52-0.25-0.39-0.49-0.530.00
Common Stock Issued16.3559.952.1423.8198.70429.65188.62340.8819.16
Common Stock Repurchased0.000.00-0.09-0.620.00-1.520.000.000.00
Other Financing Activities0.00-0.01-0.11-0.19-1.26-0.170.6617.190.89
Net Cash from Financing Activities16.1059.282.0153.08103.94427.57188.79357.5420.05
Summary
Net Change in Cash-16.69-0.81-67.10-14.39-94.32126.0913.62-18.5331.26
Cash at Beginning of Period25.1825.9993.09107.48201.8075.7162.0980.6247.97
Cash at End of Period8.4825.1825.9993.09107.48201.8075.7162.0979.22
Free Cash Flow-50.94-68.96-194.20-274.62-231.10-185.27-241.36-215.70-107.73
Supplemental Disclosures
Interest Paid-0.690.450.340.030.06---
Income Taxes Paid-0.020.000.020.020.01---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Atara Biotherapeutics Cash Flow

What is Atara Biotherapeutics's free cash flow?

Atara Biotherapeutics had negative free cash flow of $50.94M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Atara Biotherapeutics pay dividends or buy back shares?

Atara Biotherapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition